Labetalol: An Alpha- and Beta-Blocker

1983 ◽  
Vol 17 (7-8) ◽  
pp. 543-544 ◽  
Author(s):  
Christopher S. Conner
Keyword(s):  
Term Treatment ◽  
Left Ventricular ◽  
Airway Diseases ◽  
Long Term Treatment ◽  
Β Blockers ◽  
Artery Disease ◽  
Obstructive Airway Diseases ◽  
Concomitant Hypertension ◽  
Rest And Exercise

Labetalol is an investigational α- and β- adrenoreceptor antagonist. The ratio of effective β:α-blockade is approximately 7:1. Labetalol, administered intravenously or orally, has been effective in treatment of hypertension, with minimal effects on cardiac output. Labetalol will offer advantages over propranolol due to its more potent antihypertensive effects and less potent effects on left ventricular function at both rest and exercise in patients with coronary artery disease. The drug will be utilized in patients unresponsive to other β-blocking agents and in patients with congestive heart failure and concomitant hypertension, angina, or arrhythmias when other β-blockers are contraindicated. The drug appears to be safe in obstructive airway diseases and offers advantages over other β-blockers in long-term treatment after myocardial infarction.

Psychological outcomes of left ventricular assist device long‐term treatment: A 2‐year follow‐up study

2019 ◽  
Vol 44 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Alessandra Voltolini ◽  
Gerardo Salvato ◽  
Maria Frigerio ◽  
Manlio Cipriani ◽  
Enrico Perna ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Term Treatment ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Follow Up Study ◽  
Long Term Treatment ◽  
Left Ventricular Assist

Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease

2001 ◽  
Vol 157 (2) ◽  
pp. 463-469 ◽  
Author(s):  
Anthimos N Pehlivanidis ◽  
Vasilios G Athyros ◽  
Dimokritos S Demitriadis ◽  
Athanasios A Papageorgiou ◽  
Vasilios J Bouloukos ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Coronary Artery ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Artery Disease

The role of cross-sectional echocardiography in Kawasaki disease

1991 ◽  
Vol 1 (3) ◽  
pp. 221-224 ◽  
Author(s):  
José A. Ettedgui ◽  
William H. Neches ◽  
Elfriede Pahl
Keyword(s):  
Kawasaki Disease ◽  
Coronary Arteriography ◽  
Term Treatment ◽  
Left Ventricular ◽  
Arterial Stenosis ◽  
Cross Sectional ◽  
Coronary Aneurysms ◽  
Long Term Treatment ◽  
Clear Delineation

SummaryCross-sectional echocardiography is an essential tool in the evaluation ofchildren with Kawasaki disease, both in the acute and chronic stages. In the acute phase of the illness, it is valuable for diagnosis and management of pancarditis and for the long-term monitoring of pericardial effusions, left ventricular function, and the rare cases of chronic valvar dysfunction. When coronary arterial abnormalities are detected, echocardiography can serially evaluate long-term treatment with drugs which prevent the aggregation of platelets and monitor the resolution of coronary aneurysms. The value of cross-sectional echocardiography, nonetheless, is very limited in the detection of coronary arterial stenosis. Coronary arteriography is still important for the diagnosis of obstructive lesions in the coronary arteries and should be used in conjunction with cross-sectional echocardiography for the appropriate long- term management of children with Kawasaki disease at high risk of developing coronary arterial stenosis. Perhaps, in the future, high resolution transesophageal echocardiography will allow clear delineation of coronary arterial anatomy and specifically stenosis, but its role in the evaluation and management of children with Kawasaki disease remains to be explored.

Sign in / Sign up

Export Citation Format

Share Document